Endovascular Engineering, Inc.

Founded in 2019 and Endovascular Engineering, Inc. is a US-based medical technology firm dedicated to developing advanced clot removal devices for venous thromboembolism, enhancing treatment options for pulmonary embolism management. Endovascular Engineering, Inc. focuses on creating innovative medical technologies aimed at clot removal.

The company is headquartered in Menlo Park, US. Mike Rosenthal leads the firm as CEO. In April 2026, Endovascular Engineering, Inc. raised USD 80 million in series C funding co-led by new investors Gilde Healthcare and Norwest Venture Partners, with participation from returning investors Sante Ventures, 415 CAPITAL, S3 Ventures, Panakes Partners, and M&L Healthcare Investments.

Other unspecified investors also participated in the round. The company has undertaken three deals since its inception, with the most recent deal occurring on February 18, 2025. Endovascular Engineering, Inc. specializes in the development of innovative clot removal technologies, specifically targeting venous thromboembolism.

Their flagship product, the Hēlo™ PE Thrombectomy System, is designed for the effective treatment of pulmonary embolism through a unique self-expanding design that allows for optimal clot engagement with a smaller catheter profile. This technology combines high-speed agitation with physician-controlled aspiration to facilitate the breakdown and removal of clots, providing significant advantages in navigating complex anatomies. The company’s solutions are aimed at healthcare providers, particularly interventional cardiologists and radiologists, who require advanced tools for managing vascular conditions. Currently, Endovascular Engineering is focused on markets in North America and Europe, where there is a growing demand for effective embolism treatment options.

Endovascular Engineering operates within a business-to-business framework, primarily engaging with hospitals and healthcare institutions that utilize their thrombectomy systems. The company structures its transactions around the sale of medical devices, particularly the Hēlo™ PE Thrombectomy System, which is currently for investigational use only and not commercially available. Revenue generation is anticipated through partnerships with healthcare providers, focusing on deployment trials and clinical studies. As the company advances its product through the regulatory process, they may also establish pricing plans that align with the needs of their clinical partners, which typically include upfront costs related to device acquisition and potential ongoing service agreements tied to training and support.

The company plans the April 2026 funding to support its commercialization of its Hēlo Thrombectomy Platform and to invest in research and development and operations.